Methotrexaat Viatris

Methotrexate, the active ingredient in Methotrexaat Viatris, is an antimetabolite presented as a sterile solution for subcutaneous use. It interferes with folate metabolism and is employed to treat autoimmune disorders such as rheumatoid arthritis and psoriasis, as well as hematologic and solid‑tumor cancers in both adult and pediatric patients.

GNH USA supplies Methotrexaat Viatris as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Methotrexate acts as an antimetabolite that disrupts rapidly dividing cells, making it useful across several disease families.

- Rheumatoid arthritis: reduces joint inflammation and slows disease progression. - Psoriasis: improves skin lesions and decreases plaque formation. - Acute lymphoblastic leukemia: induces remission by inhibiting leukemic cell proliferation. - Non‑Hodgkin lymphoma: contributes to tumor control in combination regimens. - Osteosarcoma: enhances chemotherapy effectiveness by targeting tumor growth.

Methotrexate is associated with a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Fatigue: persistent tiredness unrelated to activity level. - Elevated liver enzymes: transient increase in hepatic transaminases.

Serious or Rare Side Effects: - Severe hepatotoxicity: potential for liver fibrosis or failure. - Pulmonary fibrosis: interstitial lung disease presenting with dyspnea. - Bone marrow failure: pancytopenia leading to infection or bleeding risk.

Before initiating therapy, clinicians should assess baseline organ function and counsel patients on potential risks.

- Monitor blood counts: perform regular complete blood count testing. - Monitor liver function: check transaminases and bilirubin periodically. - Assess renal function: evaluate creatinine clearance before dose adjustments. - Avoid use in pregnancy: teratogenic potential requires effective contraception. - Review concomitant NSAIDs: increased risk of toxicity when combined. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Methotrexate may interact with several drug classes, altering efficacy or toxicity.

Major Interactions (Avoid): - NSAIDs: can increase methotrexate plasma levels and toxicity. - Live vaccines: risk of uncontrolled infection due to immunosuppression. - Alcohol: potentiates hepatic injury.

Moderate Interactions (Monitor Closely): - Proton pump inhibitors: may affect renal clearance. - Warfarin: enhanced anticoagulant effect requiring INR monitoring. - Diuretics: can reduce renal excretion and raise drug concentrations.